STOK

SEC source: 0001780088-25-000005 · form4-12042025_011237.xml · derivative · entry 6

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,981 shares

Expires 2025-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F7 · derivative.exercise_date: 48,792 restricted stock units vested on December 1, 2024 and 11,981 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.

SEC source: 0001780088-25-000005 · form4-12042025_011237.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001522780-25-000008 · form4-12042025_011205.xml · derivative · entry 6

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,317 shares

Expires 2025-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F7 · derivative.exercise_date: 21,591 restricted stock units vested on December 1, 2024 and 4,317 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.

SEC source: 0001966716-25-000006 · form4-12042025_011223.xml · derivative · entry 6

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,357 shares

Expires 2025-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F7 · derivative.exercise_date: 33,927 restricted stock units from this award vested on December 1, 2024 and 12,357 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.

SEC source: 0001966716-25-000006 · form4-12042025_011223.xml · nonDerivative · entry 1

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001780081-25-000006 · form4-11262025_091144.xml · nonDerivative · entry 1

Krainer Adrian R. · CIK 0001780081 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 323,774

F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.12 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001780081-25-000004 · form4-11182025_091122.xml · nonDerivative · entry 2

Krainer Adrian R. · CIK 0001780081 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 364,246

F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.98 to $27.88 per share, inclusive.

SEC source: 0001780081-25-000004 · form4-11182025_091122.xml · nonDerivative · entry 1

Krainer Adrian R. · CIK 0001780081 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 384,928

F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.975 to $26.97 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3.

SEC source: 0001780088-25-000004 · form4-11052025_091154.xml · nonDerivative · entry 4

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,195

F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

SEC source: 0001780088-25-000004 · form4-11052025_091154.xml · nonDerivative · entry 3

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,295

F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.60 per share, inclusive.

SEC source: 0001780088-25-000004 · form4-11052025_091154.xml · nonDerivative · entry 2

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,895

F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.79 to $26.50 per share, inclusive.

SEC source: 0001780088-25-000004 · form4-11052025_091154.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,350

F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.74 to $25.65 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 4.

SEC source: 0001522780-25-000007 · form4-10102025_081021.xml · derivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 542,801

Underlying: Common Stock · 25,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

F2 · derivative.exercise_date: The option vested as to 1/4th of the total award on October 17, 2018, with another 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Accordingly, this stock option is now fully vested.

SEC source: 0001522780-25-000007 · form4-10102025_081021.xml · nonDerivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,124

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

SEC source: 0001522780-25-000007 · form4-10102025_081021.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,124

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

SEC source: 0001197032-25-000004 · form4-10142025_081006.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 380,000

Underlying: Common Stock · 380,000 shares

Expires 2029-10-06

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F3 · derivative.exercise_date: The award shall vest as to 1/4 of the total award annually on the sixth calendar day of October, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 6, 2026.

SEC source: 0001197032-25-000004 · form4-10142025_081006.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 570,000

Underlying: Common Stock · 570,000 shares

Expires 2035-10-07

F1 · derivative.exercise_date: The option shall vest as to 1/4 of the total award on October 6, 2026, with an additional 1/48 of the total award vesting monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date.

SEC source: 0001966716-25-000004 · form4-10072025_081001.xml · derivative · entry 3

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,800

Underlying: Common Stock · 10,000 shares

Expires 2033-03-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

F3 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award on April 15, 2023, with an additional 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001966716-25-000004 · form4-10072025_081001.xml · nonDerivative · entry 2

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,831

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001966716-25-000004 · form4-10072025_081001.xml · nonDerivative · entry 1

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,831

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

SEC source: 0001522780-25-000004 · form4-10072025_081055.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,124

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001780088-25-000003 · form4-10032025_081034.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,126

F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.40 to $24.08 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001181556-25-000006 · form4-10012025_081019.xml · derivative · entry 3

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,211

Underlying: Common Stock · 1,211 shares

Expires 2025-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award quarterly on the last day of March, June, September, and December, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001181556-25-000006 · form4-10012025_081019.xml · nonDerivative · entry 1

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-023792 · form4-09052025_080918.xml · derivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 144,000 shares

Expires 2029-03-20

F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

F4 · kind: The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The entire equity award was canceled for no consideration by mutual agreement of the reporting person and the Issuer.

F4 · price: The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The entire equity award was canceled for no consideration by mutual agreement of the reporting person and the Issuer.

F5 · derivative.exercise_date: Pursuant to the terms under which it was granted, the award was scheduled to vest as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

SEC source: 0001415889-25-023792 · form4-09052025_080918.xml · derivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 178,500 shares

Expires 2035-03-19

F1 · kind: The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The equity award was partially canceled for no consideration by mutual agreement of the reporting person and the Issuer.

F1 · price: The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The equity award was partially canceled for no consideration by mutual agreement of the reporting person and the Issuer.

F2 · derivative.exercise_date: The option began vesting on April 15, 2025. Pursuant to the terms of the initial grant, the original number of shares subject to the option vests in ratable increments monthly and the option shall be fully vested on December 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

SEC source: 0001415889-25-023590 · form4-09032025_090950.xml · nonDerivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,585

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive.

SEC source: 0001415889-25-023589 · form4-09032025_090917.xml · nonDerivative · entry 5

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,831

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.20, inclusive.

SEC source: 0001415889-25-023591 · form4-09032025_090900.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,469

F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $20.34 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-023590 · form4-09032025_090950.xml · nonDerivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 137,581

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

SEC source: 0001415889-25-023589 · form4-09032025_090917.xml · derivative · entry 7

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,801

Underlying: Common Stock · 9,150 shares

Expires 2032-12-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001415889-25-023589 · form4-09032025_090917.xml · nonDerivative · entry 4

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,176

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

SEC source: 0001415889-25-023589 · form4-09032025_090917.xml · nonDerivative · entry 3

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,098

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-023590 · form4-09032025_090950.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,441

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

SEC source: 0001415889-25-023589 · form4-09032025_090917.xml · derivative · entry 6

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,951

Underlying: Common Stock · 850 shares

Expires 2032-12-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001415889-25-023589 · form4-09032025_090917.xml · nonDerivative · entry 2

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,948

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

SEC source: 0001415889-25-023589 · form4-09032025_090917.xml · nonDerivative · entry 1

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,798

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-022442 · form4-08202025_080828.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,970

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.50 per share, inclusive.

SEC source: 0001415889-25-022441 · form4-08202025_080810.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,470

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.50 per share, inclusive.

SEC source: 0001415889-25-022440 · form4-08202025_080802.xml · nonDerivative · entry 1

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,948

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.50 per share, inclusive.

SEC source: 0001415889-25-022227 · form4-08192025_120854.xml · derivative · entry 3

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2026-08-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-25-022227 · form4-08192025_120854.xml · derivative · entry 2

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2026-08-14

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-25-022227 · form4-08192025_120854.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,775

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-022226 · form4-08192025_120830.xml · derivative · entry 3

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2026-08-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-25-022226 · form4-08192025_120830.xml · derivative · entry 2

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2026-08-14

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-25-022226 · form4-08192025_120830.xml · nonDerivative · entry 1

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-022225 · form4-08192025_120819.xml · derivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,250

Underlying: Common Stock · 26,250 shares

Expires 2026-08-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-25-022225 · form4-08192025_120819.xml · derivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,500

Underlying: Common Stock · 52,500 shares

Expires 2026-08-14

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-25-022225 · form4-08192025_120819.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,596

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-022074 · form4-08152025_080840.xml · nonDerivative · entry 1

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,631

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

F2 · balance_after: The reported total includes an aggregate 1,778 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).